TY - JOUR
T1 - TRIPODD
T2 - a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response
AU - McMahon, Nathan P.
AU - Solanki, Allison
AU - Wang, Lei G.
AU - Montaño, Antonio R.
AU - Jones, Jocelyn A.
AU - Samkoe, Kimberley S.
AU - Tichauer, Kenneth M.
AU - Gibbs, Summer L.
N1 - Funding Information:
We would like to thank Drs. Stefanie Kaech Petrie and Crystal Chaw as well as Mr. Brian Jenkins in the Advanced Light Microscopy at the Jungers Center at Oregon Health and Science University (OHSU) for expert technical assistance with fluorescence microscopy studies.
Publisher Copyright:
© 2021, World Molecular Imaging Society.
PY - 2021/10
Y1 - 2021/10
N2 - Purpose: Personalized medicine has largely failed to produce curative therapies in advanced cancer patients. Evaluation of in situ drug target availability (DTA) concomitant with local protein expression is critical to an accurate assessment of therapeutic efficacy, but tools capable of both are currently lacking. Procedure: We developed and optimized a fluorescence imaging platform termed TRIPODD (Therapeutic Response Imaging through Proteomic and Optical Drug Distribution), resulting in the only methodology capable of simultaneous quantification of single-cell DTA and protein expression with preserved spatial context within a tumor. Using TRIPODD, we demonstrate the feasibility of combining two complementary fluorescence imaging techniques, intracellular paired agent imaging (iPAI) and cyclic immunofluorescence (cyCIF), conducted with oligonucleotide-conjugated antibodies (Ab-oligos) on tissue samples. Results: We successfully performed sequential imaging on a single tissue section of iPAI to capture single-cell DTA and local protein expression heterogeneity using Ab-oligo cyCIF. Fluorescence imaging data acquisition was followed by spatial registration resulting in high dimensional data correlating DTA to protein expression at the single-cell level where uptake of a targeted probe alone was not well correlated to protein expression. Conclusion: Herein, we demonstrated the utility of TRIPODD as a powerful imaging platform capable of interpreting tumor heterogeneity for a mechanistic understanding of therapeutic response and resistance through quantification of drug target availability and proteomic response with preserved spatial context at single-cell resolution.
AB - Purpose: Personalized medicine has largely failed to produce curative therapies in advanced cancer patients. Evaluation of in situ drug target availability (DTA) concomitant with local protein expression is critical to an accurate assessment of therapeutic efficacy, but tools capable of both are currently lacking. Procedure: We developed and optimized a fluorescence imaging platform termed TRIPODD (Therapeutic Response Imaging through Proteomic and Optical Drug Distribution), resulting in the only methodology capable of simultaneous quantification of single-cell DTA and protein expression with preserved spatial context within a tumor. Using TRIPODD, we demonstrate the feasibility of combining two complementary fluorescence imaging techniques, intracellular paired agent imaging (iPAI) and cyclic immunofluorescence (cyCIF), conducted with oligonucleotide-conjugated antibodies (Ab-oligos) on tissue samples. Results: We successfully performed sequential imaging on a single tissue section of iPAI to capture single-cell DTA and local protein expression heterogeneity using Ab-oligo cyCIF. Fluorescence imaging data acquisition was followed by spatial registration resulting in high dimensional data correlating DTA to protein expression at the single-cell level where uptake of a targeted probe alone was not well correlated to protein expression. Conclusion: Herein, we demonstrated the utility of TRIPODD as a powerful imaging platform capable of interpreting tumor heterogeneity for a mechanistic understanding of therapeutic response and resistance through quantification of drug target availability and proteomic response with preserved spatial context at single-cell resolution.
KW - Cancer heterogeneity
KW - Cyclic immunofluorescence
KW - Drug target engagement
KW - Fluorescence imaging
KW - Intracellular paired agent imaging
UR - http://www.scopus.com/inward/record.url?scp=85102353025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102353025&partnerID=8YFLogxK
U2 - 10.1007/s11307-021-01589-x
DO - 10.1007/s11307-021-01589-x
M3 - Article
C2 - 33751366
AN - SCOPUS:85102353025
SN - 1536-1632
VL - 23
SP - 650
EP - 664
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 5
ER -